[{"Assets_0_Q3_USD":451050000.0,"CommonStockSharesOutstanding_0_Q3_shares":30150577.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":-10708000.0,"NetIncomeLoss_1_Q3_USD":-11265000.0,"NetIncomeLoss_3_Q3_USD":-39598000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q3_shares":30123188.0,"WeightedAverageNumberOfSharesOutstandingBasic_3_Q3_shares":29997201.0,"StockholdersEquity_0_Q3_USD":244302000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q3_USD":95630000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_3_Q3_USD":279345000.0,"Ticker":"NVRO","CIK":"1444380","name":"NEVRO CORP","OfficialName":"Nevro Corp. Common Stock","form":"10-Q","period":"20180930","fy":"2018.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"2648227724.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Electromedical & Electrotherapeutic Apparatus","Market":"NYSE","SP500":"nan","filed":"20181105"}]